Objectives/Goals: This study evaluates the impact of a pharmacist-delivered peer educational intervention on buprenorphine dispensing behavior for opioid use disorder (OUD) in Appalachian Kentucky. Methods/Study Population: Based on themes from focus group analyses of our prior work, we developed a pharmacist-delivered peer educational intervention consisting of brief, on-site academic detailing sessions (i.e., mini visits) and live continuing pharmacy education webinars. Trained academic detailing pharmacists conducted mini-visits to 113 community pharmacies across 23 counties (20 lowest and 3 of the next 5 lowest buprenorphine dispensing rates per individual with OUD), providing materials while webinars reinforced confidence and addressed stigma. Changes in pharmacists’ self-reported buprenorphine dispensing behaviors were evaluated using a validated pre-post survey offered to all pharmacists in each pharmacy. Analyses used unpaired t-tests for continuous scores variables and chi-square for categorical variables Results/Anticipated Results: A total of 128 of 131 participants (97.7%) completed the pre-survey and 95 of 131 (72.5%) completed the post-survey. Sex was similar between individuals in the pre- and post-surveys (50.0% vs 52.6% female, P=0.7). Most worked in independent pharmacies (64.8% pre, 67.4% post) and had ≥10 years in practice (63.3% pre, 68.4% post). Buprenorphine dispensing was reported by 85.9% pre and 88.3% post. After the intervention, participants showed greater willingness for telehealth prescriptions, with a mean change of +0.2 points (95% CI: 0.001–0.46, P = 0.0038) on a four-point scale. They also reported more welcoming environments toward individuals receiving buprenorphine treatment (five-point scale; mean change: +0.4, 95% CI: 0.05–0.8, P = 0.027). Discussion/Significance of Impact: Our pharmacist-delivered peer intervention enhanced pharmacists’ willingness to dispense buprenorphine via telehealth and fostered supportive pharmacy environments. Next, we will assess its effectiveness in expanding buprenorphine treatment access across Kentucky using county-level dispensing data.
Oladapo et al. (Wed,) studied this question.